Webinar
Have we finally reached the end of in vitro testing? Positioning NGS in cell and gene therapy biosafety testing
🗓️ April 21, 2026
🕘 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
👤 Online Webinar
Join our upcoming webinar to explore how transcriptome-based Next Generation Sequencing (NGS) is transforming viral safety testing in cell and gene therapy manufacturing. As advanced therapies continue to evolve, ensuring robust viral safety strategies has become increasingly critical for product quality and regulatory compliance. NGS offers a comprehensive approach capable of detecting a wide range of viruses with greater sensitivity and speed than many traditional methods.
With broader detection capabilities, higher sensitivity, and faster turnaround times, transcriptome-based NGS is emerging as a powerful alternative to conventional PCR-based and animal-derived assays. By enabling the simultaneous identification of multiple viral contaminants within a single workflow, NGS supports more efficient biosafety testing and helps manufacturers strengthen risk-based viral safety strategies.
Attend this webinar to:
- Understand how iDTECT® Transcriptome-based NGS can serve as a single alternative to multiple legacy viral safety assays, including HAP/MAP/RAP panels, PCR, and 9 CFR tests
- Review data from a joint study conducted by PathoQuest and Charles River Laboratories validating detection of required, known, and novel viruses
- Identify opportunities to consolidate viral safety workflows and support regulatory discussions through risk-based assessment
🎤 Speaker
Colette Côté, PhD
Chief Scientific and Portfolio Officer & US General Manager, PathoQuest
👉 Register now to learn how NGS can support modern viral safety strategies for CGT manufacturing workflows.
Don’t miss this opportunity to gain practical insights from industry experts.
